Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (8567)	2/1/1999 4:20:00 PM
From: Kushi Kullar	Read Replies (1) \| Respond to of 17367

Does it make sense to sell now and wait for "approval"? It does not seem that Scios was helped much by approval. Is the risk worth holding through approvel?

To: Bluegreen who wrote (8567)	2/1/1999 4:32:00 PM
From: Edward Paule	Read Replies (1) \| Respond to of 17367

All, My observations: Without the $12 million in funding from this latest financing, XOMA had enough cash to last 5 months. The trial ends in March, plus the 90-day follow up period, equals 5 months until XOMA knows if rBPI-21 works. IMO, that's too close for comfort. Many companies that are running low on cash, that are anticipating good news in the near future, often do these little 3 month financing deals. $12 million is 3 months for XOMA. Doing a financing for more than 3 months is considered too much unnecessary dilution and less than 3 months is considered a waste of overhead in doing multiple small financing deals one after another. Why did XOMA do the financing now instead of in March or April? Since XOMA has no control over ending the trial, April could arrive without an end to the trial, with a more immediate need to raise cash, with the stock trading at $3. XOMA did the conservative thing. All IMO, Ed.